HIGHLIGHTS
SUMMARY
In the past decade, the pharmaceutical market has increased at a slower pace than before, due to patent expiries of several blockbuster 2 of 20 drugs and the economic crisis, which also influenced the national health cost-containment policies. European policy-makers recognized high drug prices as the main challenge to overcome to provide access to new therapies, remaining within the limits of the national health budget. This can lead to a sensible reduction of costs, increasing patients` access to innovative drugs, and at the same time containing pharmaceutical expenditure within the national healthcare . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.